Theramex
https://www.theramex.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Theramex
Enzene CEO On Biosimilar Denosumab And Cetuximab; Medicare Negotiation Impact On US Market
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.
TherapeuticsMD Finds New Exit With Mayne Pharma Licensing Pact
After failure to close of a potential $177m buyout by EW Pharma, TherapeuticsMD will resolve its debt by selling its three-product women’s health portfolio to Mayne.
ObsEva Slashes 70% Of Staff To Survive
Having surrendered the rights to linzagolix, its GnRH antagonist for bleeding associated with uterine fibroids that the FDA blocked, ObsEva is showing the door to most of its staff in a bid to cut costs and keep in business.
Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval
Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- CVC Capital Partners SICAV-FIS S.A.
- CVC Capital Partners
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice